Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients

March 25, 2021 updated by: Burcu Deniz Gunes, Aydin Adnan Menderes University

Evaluation of the Effect of Mediterranean Diet on Body Composition, Oxidant Stress and Proinflammatory Markers in Breast Cancer Patients

In this study, it was aimed to evaluate the effect of the Mediterranean diet on body composition, oxidant stress and proinflammatory markers in overweight and obese breast cancer women.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Breast cancer is the most common type of cancer among women in both developed and developing countries and is the leading cause of cancer death among women worldwide. Breast cancer is a disease that can develop and progress for various reasons. In addition to unchangeable factors such as increasing age and genotype, modifiable factors such as smoking, alcohol consumption, lack of physical activity, malnutrition, and obesity play a role in the pathogenesis of the disease.

Breast cancer risk increases with increasing body mass index (BMI) in postmenopausal women. Chronic inflammation in obesity is associated with an increase in the release of proinflammatory factors (such as TNF-α, IL-1, IL-6). This situation; It is a risk factor for many types of cancer such as colon, stomach, breast and prostate carcinomas and supports a cause-effect relationship between obesity and cancer. These proinflammatory factors act as signal converters for tumor growth and progression. Obese women have elevated levels of TNF-α and IL-6 in the circulation, and this is associated with the development and progression of breast tumors.

The Mediterranean Diet, which consists of high amounts of monounsaturated fatty acids, fruits, vegetables and whole grains, has been widely evaluated and indicated as an important factor in preventing tumor formation from inflammatory pathways.

Weight loss improves the antitumor immune system, lowers estrogen levels, reduces the risk of breast cancer and has been associated with better outcomes in obese patients. Lifestyle intervention studies strongly suggest that weight loss is possible and observational studies can actually improve breast cancer survival.In this regard, a healthy lifestyle and diet are the first steps to prevent breast cancer.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Efeler
      • Aydın, Efeler, Turkey, 09100
        • Aydın Adnan Menderes University, Faculty of Health Sciences, Department of Nutrition and Dietetics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • At least 18 years old,
  • BMI value to be ≥25 kg/m2,
  • To be diagnosed with breast cancer stage I, II or III,
  • Being a positive hormone receptor status, one of the biological subtypes of breast cancer,
  • Having completed chemotherapy and / or radiotherapy treatment at least 6 months before starting the study,
  • Not applying any treatment for body weight loss,
  • Accepting to participate in the study,
  • Perceiving disorder and not having communication problems.

Exclusion Criteria:

  • Being under the age of 18 and over the age of 65,
  • BMI value to be 40 kg/m2,
  • Having advanced stage breast cancer (IV and V),
  • Being diagnosed with cancer or metastasis in other organs,
  • Being one of the biological subtypes of breast cancer, hormone receptor status being negative,
  • Using antioxidant vitamin-mineral supplements,
  • Using herbal supplements,
  • Being pregnant or planning a pregnancy,
  • To stop working after starting diet therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Mediterranean Diet
In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.

While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).

In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in body weight
Time Frame: Baseline, 8 weeks
Body weight (kg) was measured using the InBody 270 brand device.
Baseline, 8 weeks
Change in body mass indexs
Time Frame: Baseline, 8 weeks
The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m^2, resulting from mass in kilograms and height in metres.
Baseline, 8 weeks
Change in fat mass measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
Fat mass (kg) was measured using the InBody 270 brand device.
Baseline, 8 weeks
Change in fat-free mass measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
Fat-free mass (kg) was measured using the InBody 270 brand device.
Baseline, 8 weeks
Change in resting metabolic rate (RMR) measured by bioelectrical impedance analyzer
Time Frame: Baseline, 8 weeks
RMR (kcal) was measured using the InBody 270 brand device.
Baseline, 8 weeks
Change in interleukin 6 (IL-6)
Time Frame: Baseline, 8 weeks
Blood was drawn from participants for assessment of IL-6 (pg/mL) at the beginning and end of the study after fasting for at least 8 hours
Baseline, 8 weeks
Change in tumor necrosis factor alpha (TNF-α)
Time Frame: Baseline, 8 weeks
Blood was drawn from participants for assessment of TNF-α (pg/mL) at the beginning and end of the study after fasting for at least 8 hours
Baseline, 8 weeks
Change in malondialdehyde (MDA)
Time Frame: Baseline, 8 weeks
Blood was drawn from participants for assessment of MDA (mmol/L) at the beginning and end of the study after fasting for at least 8 hours
Baseline, 8 weeks
Change in total antioxidant status (TAS)
Time Frame: Baseline, 8 weeks
Blood was drawn from participants for assessment of TAS (mmol/L) at the beginning and end of the study after fasting for at least 8 hours
Baseline, 8 weeks
Change in total oxidant status (TOS)
Time Frame: Baseline, 8 weeks
Blood was drawn from participants for assessment of TOS (µmol/L) at the beginning and end of the study after fasting for at least 8 hours
Baseline, 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in waist circumference
Time Frame: Baseline, 8 weeks
Waist circumference (cm) was measured with a non-stretch tape measure.
Baseline, 8 weeks
Change in hip circumference
Time Frame: Baseline, 8 weeks
Hip circumference (cm) was measured with a non-stretch tape measure.
Baseline, 8 weeks
Change in dietary inflammatory index (DII)
Time Frame: Baseline, 8 weeks
Dietary inflammatory index (DII) was calculated with 3-day food consumption record.
Baseline, 8 weeks
Change in oxidative stress index (OSI)
Time Frame: Baseline, 8 weeks
The oxidative stress index (OSI) value expressed as a percentage of the ratio of serum total oxidant status (TOS) levels to total antioxidant status (TAS) levels was calculated.
Baseline, 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Burcu Deniz Güneş, Aydın Adnan Menderes University, Faculty of Health Sciences, Department of Nutrition and Dietetics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 22, 2019

Primary Completion (ACTUAL)

December 17, 2019

Study Completion (ACTUAL)

January 20, 2021

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

March 25, 2021

First Posted (ACTUAL)

March 26, 2021

Study Record Updates

Last Update Posted (ACTUAL)

March 26, 2021

Last Update Submitted That Met QC Criteria

March 25, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

IPD Sharing Time Frame

6 months after publication

IPD Sharing Access Criteria

relevance to the topic of the study and approval of all co-authors within 1 month of receiving the request.

IPD Sharing Supporting Information Type

  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Mediterranean Diet

Subscribe